NIVALLO : Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Lymphoblastic Leukaemia,Acute Lymphoblastic Lymphoma,Acute Myeloid Leukaemia,Acute Promyelocytic Leukaemia,B-Cell Non Hodgkin Lymphoma,Chronic Lymphocytic Leukaemia,Chronic Myelogenous Leukaemia,Diffuse Large Cell Lymphoma,Follicular Lymphoma,Hodgkin's Disease (Hodgkin's Lymphoma),Leukaemia,Lymphoma,Mantle Cell Lymphoma,Multiple Myeloma,Skin Lymphoma,T-Cell Lymphoma

Trial Overview Read MoreRead more

This phase I/II trial is testing the safety of an immunotherapy (Nivolumab) for patients whose blood cancer has relapsed following blood or bone marrow transplantation.
 

This trial is treating patients with blood cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation

Commercial Sponsor

Bristol-Myers Squibb (BMS)

Other Non-Commercial Sponsor

Melbourne Health

Summary

All participants in this non-randomised trial will receive intravenous Nivolumab (3mg/kg) every two weeks for up to 48 weeks.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next